Literature DB >> 2665855

Down-modulation of neutrophil production by erythropoietin in human hematopoietic clones.

R D Christensen1, J M Koenig, D H Viskochil, G Rothstein.   

Abstract

In clonogenic assays of hematopoietic progenitors, high concentrations (4 U/mL) of erythropoietin (epo) reduced the formation of granulocyte-macrophage (GM) colonies and diminished the number of granulocytes formed per culture plate. Fetal progenitors were more sensitive to these effects of epo than were progenitors from adults, displaying these reductions at greater than or equal to 1 U epo/mL. The mechanism was investigated by growing fetal progenitors stimulated by recombinant GM-CSF, in the absence of epo, and when eight-cell clones first appeared, mapping their location, then adding epo, and assessing its effect on the subsequent differentiation of the clones. In the absence of epo, the clones developed exclusively into GM colonies. However, if developing clones were presented with epo, 85% matured into GM colonies, but 15% became multilineage or normoblast colonies. In addition, developing clones that were presented with epo produced colonies that contained fewer neutrophils. These effects of epo on neutrophil generation were observed with each of three varieties of recombinant epo, and also with purified human epo, but were not observed using epo that had been neutralized with rabbit anti-epo antiserum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665855

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Anaemia of prematurity. Epidemiology, management and costs.

Authors:  M P Meyer
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

2.  Double blind trial of recombinant human erythropoietin in preterm infants.

Authors:  A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

3.  Weekly intravenous administration of recombinant human erythropoietin in infants with the anaemia of prematurity.

Authors:  D Beck; E Masserey; M Meyer; A Calame
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

Review 4.  Pharmacological approaches to reduce perioperative transfusion requirements in the aged.

Authors:  T Tasaki; H Ohto; R Motoki
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

5.  Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity.

Authors:  D S Halpérin; M Félix; P Wacker; G Lacourt; J F Babel; M Wyss
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 6.  Age-Appropriate Functions and Dysfunctions of the Neonatal Neutrophil.

Authors:  Shelley Melissa Lawrence; Ross Corriden; Victor Nizet
Journal:  Front Pediatr       Date:  2017-02-28       Impact factor: 3.418

7.  Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection.

Authors:  Bongki Cho; Seung-Jun Yoo; So Yeon Kim; Chang-Hun Lee; Yun-Il Lee; Seong-Ryong Lee; Cheil Moon
Journal:  Redox Biol       Date:  2021-12-21       Impact factor: 11.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.